Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIOSA: Mirvetuximab Soravtansine + Bevacizumab in Ovarian Cancer
NCT05445778Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Progression-Free Survival up to 4 years. Started Mar 2023; status: active, not recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05445778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445778.